par Lakshmaiah, Kuntegowdanahalli;Kumar, Anil A.N.;Purohit, Samit;Viveka, Belathur;Rajan, Kamalakannan K.R.;Zameer, Mohammed Abdul L;Namitha, Prabhu;Saini, Monika Lamba;Abdel Azim, Hatem Hamdy 
;Saini, Kamal
Référence Hereditary Cancer in Clinical Practice, 12, 1, 5
Publication Publié, 2014-02
;Saini, Kamal Référence Hereditary Cancer in Clinical Practice, 12, 1, 5
Publication Publié, 2014-02
Article révisé par les pairs
| Résumé : | The association of neurofibromatosis type I with invasive male breast cancer is a rare clinical entity with only one case in literature reported in 1953. Women with NF1 are at risk of developing breast cancer and men also may be at risk but there is scarce data on the risk and association of NF1 with male breast cancer due to its rarity. Established clinical trials in male breast cancer patients are lacking and the results are extrapolated from female breast cancer patients. The treatment of male breast cancer is followed as per the guidelines of premenopausal female breast cancer and tamoxifen is the hormone treatment in them. Mendes et al suggests that silencing of NF1 gene confers resistance to tamoxifen. Our conclusions are that since NF1 is mutated or deleted in one third of sporadic breast cancers, its role as a molecular driver for treatment has to be further explored. © 2014 Lakshmaiah et al.; licensee BioMed Central Ltd. |
